<DOC>
	<DOCNO>NCT01328938</DOCNO>
	<brief_summary>This study adaptive design consist stage I stage II . Stage I multi-center , parallel-group , single-blind , phase II study determine adequate dose GCPGC chemotherapy-induced neutropenia . 2 Different dos GCPGC investigate total 60 Breast cancer patient receive chemotherapy . Stage II multi-center , parallel-group , double-blind , phase III study evaluate efficacy safety per cycle GCPGC chemotherapy-induced neutropenia compare Neulasta ( pegfilgrastim ) . A total 120 patient receive chemotherapy participate phase .</brief_summary>
	<brief_title>GCPGC Chemotherapy-induced Neutropenia</brief_title>
	<detailed_description>GCPGC ia solution contain pegfilgrastim . Pegfilgrastim covalent conjugate recombinant human granulocyte colony-stimulating factor ( G-CSF ) polyethylene glycol ( PEG ) long half life compare filgrastim , result dosing advantage .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>woman ( ≥ 18 year old ) diagnose breast cancer receive chemotherapy induce neutropenia body weight 45kg ECOG performance status 2 less ANC ≥1,500mm3 Platelet ≥100,000/mm3 life expectancy 3 month give write informed consent previous exposure pegfilgrastim filgrastim receive systemic antibiotic within 72hrs chemotherapy prior total cumulative lifetime exposure doxorubicin 240 mg/m epirubicin 600 mg/m</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Pegfilgrastim</keyword>
	<keyword>neutropenia</keyword>
</DOC>